Our Talent Acquisition team enjoying our summer BBQ for GHI employees! So much fun. Just another example of how we build community here at Genomic Health.
#team #talentacquisition #employees #somuchfun
Congrats to Dr. Steven Shak, our co-founder, recognized as a pioneer and visionary for his work in personalized medicine to revolutionize cancer care!
http://glassdoor.com/slink.htm?key=vMFFd #personalizedmedicine #cancercare #visionary #founder #pioneer
The No Matter My Age campaign focuses on raising awareness about the need for all breast cancer patients, regardless of age, to get as much information as they can before making a treatment decision.
Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
We’re pleased to share the first story that aired on NBC in Columbus, Ohio featuring Deepa Halaharvi. The segment includes an interview with Deepa about her experience with Oncotype DX as both a physician and patient. It also highlights the TAILORx results and that NCCN considers the Oncotype DX test a “preferred method.” You can view the story on NBC’s website. Enjoy!
We are pleased to announce the publication of results of a large prospective trial validating the detection of AR-V7 biomarker using Epic Sciences AR-V7 test, commercialized in the US as Oncotype DX® AR-V7 Nucleus Detect™by Genomic Health. Press release: http://glassdoor.com/slink.htm?key=vMCfp
#ARV7 #JCOCCI #genomichealth
Listen to Bret Miller discuss his experience with hashtag#Oncotype DX and how the test played an instrumental role in his hashtag#breastcancer treatment decision.
Intern Poster Fair 2018
"Genomic Health Employees Doing Life, Changing Work"